摘要
目的：分析急性髓系白血病（AML）患者诱导缓解后应用大剂量阿糖胞苷（HD-AraC）巩固治疗的疗效，探讨HD-AraC的安全性及应用前景。方法初诊及复发AML患者67例，诱导缓解后予1~4个疗程HD^AraC巩固治疗：Ara-C 1.5~3.0 g/（m2·次），1次/12h，静脉滴注持续3h，第1、3、5天，共6次。分析HD-AraC的毒副作用及对未行移植的51例患者进行生存分析。结果51例患者1年及2年总生存率（OS）分别为78%和69%，1年及2年无复发生存率（RFS）分别为74%和62%；51例患者中复发11例，复发率21.56%，死亡8例，死亡率15.46%。危险分层低、中、高危三组患者的OS及RFS差异均有统计学意义（P=0.024，0.009）。结论 HD-AraC巩固治疗相关病死率为1.5%，耐受性好，低危组患者OS及RFS明显优于中危及高危组。年龄、诱导方案、初诊WBC对预后无影响。
Objective To analysis the effects of high-dose cytarabine as consolidation chemotherapy for AML after induction remission,to investigate the safety and application prospects of high-dose cytarabine. Methods 67 cases after induction remission received HD-AraC （1.5~3g/m-2 per 12 hours by three-hour infusion day1,3,5）as post-remission treatment for 1~4 cycles. Assess the toxic effects of high-dose cytarabine,and analysis the survival of 51 cases who did not undergo the hematopoietic stem cell transplantation. Results 1 year OS and RFS were 78%and 74%,2 year OS and RFS were 69%and 62%,relapse rate was 21.56%, death rate was 15.46%. OS and RFS）were significant different for different prognosis group （P=0.024,0.009）. Conclusions HD-AraC was well tolerated in AML patients as post-remission therapy,the treatment-related mortality rate was 1.5%. The OS and RFS of low-risk group were better than intermediate-risk and high-risk group,the difference was significant. The age,induction program and WBC were no significant for OS and RFS.
出处
《浙江临床医学》
2014年第5期686-688,共3页
Zhejiang Clinical Medical Journal
关键词
急性髓系白血病
阿糖胞苷
巩固治疗
疗效分析
Acute myeloid leukemia
Cytarabine
Consolidation therapy
Efficacy analysis
